My watch list  


Systematic (IUPAC) name
CAS number 3239-44-9
ATC code A08AA04
PubChem 3337
DrugBank APRD00648
Chemical data
Formula C12H16F3N 
Mol. mass 231.257 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 36%
Metabolism  ?
Half life 17-20 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status

Schedule IV (US DEA)

Routes  ?

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.

The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.

See also


  • FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dexfenfluramine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE